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Background: In 2000/2001, the Australian Defense Forces (ADF), in collaboration with SmithKline Beecham and the
United States Army, conducted a field trial to evaluate the safety, tolerability and efficacy of tafenoquine and mefloquine/
primaquine for the prophylaxis of malaria amongst non-immune Australian soldiers deployed to East Timor (now called
Timor Leste) for peacekeeping operations. The lack of a concurrent placebo control arm prevented an internal estimate of
the malaria attack rate and so the protective efficacy of the study regimens was not determined at the time.
Methods: In a retrospective analysis of the trial results, the all species malaria attack rate was estimated for the
prophylactic phase of the study which was defined as the period between administration of the first prophylactic dose
and the first dose of post-deployment medication. First, the Plasmodium vivax attack rate was estimated during the
prophylactic phase of the deployment by adjusting the observed P. vivax relapse rate during post-deployment to account
for the known anti-relapse efficacies (or effectiveness) of the study medications (determined from prior studies). The all
species malaria attack rate (P. vivax and Plasmodium falciparum) was then determined by adjusting the P. vivax attack rate
based on the ratio of P. falciparum to P. vivax observed during prior ADF deployments to Timor Leste. This estimated all
species malaria attack rate was then used as the ‘constant estimated attack rate’ in the calculation of the protective
efficacy of tafenoquine and mefloquine during the prophylactic phase of the deployment.
Results: The estimated attack rate during the prophylactic phase of the study was determined to be 7.88%. The
protective efficacies of tafenoquine and mefloquine, with corresponding 95% confidence intervals (95% CI), were
determined to be 100% (93%-100%) and 100% (79%-100%) respectively.
Conclusions: The protective efficacy of tafenoquine (200 mg per day for three days, followed by weekly 200 mg
maintenance doses) is similar to that of the weekly standard of care (mefloquine, 250 mg).Background
Tafenoquine is a long elimination half-life [1] primaquine
analog that has the potential to replace mefloquine for
weekly malaria chemoprophylaxis. Tafenoquine was evalu-
ated in a series of placebo-controlled studies in mixed or
semi-immune residents of Africa and Southeast Asia in
the late 1990s [2-4]. The weekly standard of care, meflo-
quine, was also evaluated in some of the same studies.
The protective efficacies (95% CI) of tafenoquine at the* Correspondence: geoffdow@hotmail.com
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reproduction in any medium, provided the orintended dose (200 mg per day for three days followed by
weekly 200 mg maintenance doses) and mefloquine in
semi-immune residents of Ghana were 86% (76-92%) and
86% (72-93%) respectively [2]. In a second study in
semi-immune residents of Kenya, the protective efficacy
of tafenoquine was reported to be 86% (73-93%) [3]. For a
discussion of the use of placebo control arms in malaria
chemoprophylaxis studies in which semi-immune individ-
uals are enrolled, see [5].
In 2000/2001, the safety, tolerability and efficacy of
weekly tafenoquine and mefloquine were evaluated in
malaria non-immune Australian soldiers from the 1st
Battalion, Royal Australian Regiment (1RAR) deployed ond. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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teered to participate in a Phase 3 study [6]. In that study,
which is referred to as Study 033 from here on, the pro-
tective efficacy of tafenoquine was not calculated because
the study lacked a concurrent placebo control arm. A pla-
cebo control arm was not employed in Study 033 since
the study volunteers were simultaneously participating in
an ongoing peacekeeping operation and a placebo control
arm was not considered appropriate in this context be-
cause malaria disrupts operational effectiveness. However,
the study team concluded that both tafenoquine and mef-
loquine were effective since no malaria cases were ob-
served during the prophylactic phase of the study, and the
observation of Plasmodium vivax relapses during follow-
up, together with epidemiology data from military and ci-
vilian sources suggested substantial exposure to malaria
[7-10].
The United States Food and Drug Administration (FDA)
[11] has stated: “The deployment of military personnel or
civilian cohorts to malaria-endemic regions provides an
opportunity to study anti-malarial prophylaxis in malaria-
naive subjects. Since such deployments may last for many
months, it is possible to standardize duration of malaria
exposure. When placebo-controlled studies cannot be
performed, well-characterized epidemiological attack rates
can be used to calculate protective efficacy”. Furthermore,
the FDA [11] also recommends that the calculation of
protective efficacy in historical-controlled studies should
employ epidemiological attack rates in the study area from
at least the past two malaria seasons. In addition, these
epidemiological attack rates should closely reflect antici-
pated attack rates in the study population and should be
derived from the same geographical area, during the same
seasonal period, with similar rainfall and similar subject
exposure.
Malaria epidemiological data were collected from ADF
personnel deployed to Timor Leste in the year prior to
Study 033 [12]. That study reported an attack rate of ~4.8%
across all deployed military personnel. These data do not
completely meet the requirements of the FDA guidance
[11] for two reasons. First, the data were collected only for
a single year. Second, the operational environment changed
between 1999/2000 and 2000/2001, meaning that we do
not know whether exposure of ADF personnel to mal-
aria remained constant. Malaria prevalence was measured
amongst civilians who were not taking prophylaxis in
villages adjacent to garrisoned Australian soldiers dur-
ing Study 033 [7]. Similar data are not available for the
prior year, so cannot be used to directly link exposure in
Australian soldiers in the two deployments.
Immunologic markers of malaria exposure continue to
be explored as a possible surrogate for observed malaria
cases in malaria prophylaxis studies in which a placebo
control arm was not used. Antibodies to circumsporozoiteprotein were measured as a secondary endpoint in the
atovaquone-proguanil clinical development program [13].
However, in that study, seroconversion was only 1.1%, and
since there were no confirmed symptomatic cases, it is
unclear to what extent this reflects true exposure. The US
Army recently investigated the possibility that antibodies
to merozoite surface protein 1 (MSP1) might serve as a
surrogate marker of malaria exposure in non-immune in-
dividuals given mefloquine for prophylaxis [14]. Regula-
tory agencies have not yet embraced the use of such
surrogates [11], although it is possible they might if more
compelling evidence of their utility became available. In
any case, since they are not currently available, a retro-
spective analysis of stored blood samples, even if feasible,
would likely not reveal useful information regarding mal-
aria exposure during Study 033.
Because of the limitations stated above, an alternative
approach was needed to satisfy the FDA’s requirement
that a well-characterized epidemiological attack rate should
be used to calculate protective efficacy when a placebo
control arm is not appropriate. To this end, the P. vivax
attack rate during the prophylactic phase of Study 033
in Timor Leste was estimated through adjustment of
the observed post-deployment P. vivax relapse rate dur-
ing the follow-up period of the study to account for the
known anti-relapse efficacies (or effectiveness) of the study
medications. This methodological separation between what
would have been primary P. vivax cases during deployment
and post-deployment relapses is reasonable, because, while
both events are triggered by the same initial exposure, they
are independent clinical episodes prevented through in-
dependent pharmacologic modalities that pose different
risks to the individual and deployed force. An all malaria
attack rate was estimated by adjusting the P. vivax
attack based on the ratio Plasmodium falciparum to
P. vivax cases observed amongst Australian soldiers in
Timor Leste a year prior to Study 033. The estimated
all malaria attack rate was then utilized to determine,
retrospectively, the protective efficacy of both tafenoquine
and mefloquine in Study 033 so a comparison could be
made to the placebo controlled studies in semi and mixed
immune populations.Methods
Definition of prophylactic efficacy
For the purposes of this study the definition of protect-
ive efficacy is the same as was used in the original Study
033 protocol: Ability of study medications with recorded
administration to prevent clinical malaria (single positive
smear of any species with concurrent signs and symp-
toms consistent with malaria infection) during prophy-
lactic study drug administration up to and including the
first dose of post-deployment medication.
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For the purposes of this study, anti-relapse efficacy/effect-
iveness is the degree to which observed (or unsupervised)
tafenoquine and primaquine administration can prevent
P. vivax relapses. There was no distinction made here be-
tween the intent or possible timing of 8-aminoquinoline
administration, whether it be following a course of sup-
pressive prophylaxis, an additional property of an anti-
malarial drug also being used in a prophylactic mode, or
in sequential combination with a blood schizonticidal
drug to treat symptomatic P. vivax. In the case of histor-
ical estimates of the utility of primaquine, we have used a
meta-analysis of effectiveness data [15], since many of the
input studies utilized unsupervised primaquine regimens.
The corresponding tafenoquine data represent the efficacy
of the drug since the studies from which they were derived
involved observed use of the drug.
Primary P. vivax attacks during deployment and
post-deployment relapses are not the same
Post-deployment P. vivax relapses are not the same as
primary P. vivax attacks occurring during deployment
because while triggered by the same initial exposure, are
independent clinical events prevented through independent
pharmacologic modalities and which pose different risks to
the individual and deployed forces.
During a visit to a malarious area, non-immune individ-
uals exposed to P. vivax will experience a primary symp-
tomatic attack and if treated with anti-malarial drugs to kill
asexual blood stages may still go on to experience one or
more hypnozoite-intiated relapses. To prevent such pri-
mary attacks during travel or deployment it is conventional
to administer a prophylactic that inhibits the development
of asexual blood stages or exoerythrocytic stages (or both)
in the liver. Since these properties of a prophylactic drug
do not prevent the establishment of the P. vivax hypno-
zoite, many individuals who receive such a drug will ex-
perience one or more post-deployment relapses rather
than a primary attack.
Independent post-deployment administration of prima-
quine substantially reduces, but not to zero, the number
of P. vivax relapses due to the effect of the drug on hypno-
zoites [15,16]. This anti-hypnozoite activity is mediated in-
dependently of the other effects of primaquine on asexual
blood and developing exoerythrocytic stages. The same
logic holds for tafenoquine, since the drug exhibits a
measurable inhibitory effect on P. vivax hypnozoites inde-
pendent of its other actions on asexual blood stages and
developing exoerythrocytic parasites in the liver [4,17,18].
Based on the World War II experience with malaria in
the Pacific theatre [19], it seems intuitive that the man-
agement of a small number of individuals with P. vivax
hypnozoites refractory to primaquine (or tafenoquine) is
more straight-forward and has less operational impactthan a larger number of primary attacks in theatre (in the
absence of effective prophylaxis). In contrast, an individual
who takes effective prophylaxis without an 8-amino-
quinoline is at greater risk of repeated post-deployment
P. vivax relapses despite having being exposed only once
and never experiencing a primary attack. Furthermore,
the clinical impact of a primary attack on a traveller may
be greater than a relapse in their own country if they do
not have access to good medical care while travelling.
Therefore, the deployment prophylactic and anti-relapse
efficacies of proposed interventions can and should be
measured independently. As a first step towards calcula-
tion of the former, an estimate of the attack rate is re-
quired. In this study, since the post-deployment relapse
rate is known, and the anti-relapse efficacy of the com-
bined study regimens can be estimated, it is possible to es-
timate the number of individuals exposed to P. vivax
during a deployment.
Summary of study 033
From October 2000 through April 2001, the 1RAR was
deployed to Timor Leste from Australia for peacekeeping
operations [6]. Six hundred and fifty four of these soldiers
volunteered to participate in Study 033, and were random-
ized to receive either tafenoquine (n = 492) or mefloquine
(n = 162) for malaria prophylaxis. Tafenoquine was admin-
istered as a loading dose of 200 mg once per day for three
days, followed by weekly 200 mg maintenance doses.
Mefloquine was administered as a 250 mg loading dose
once per day for three days followed by weekly 250
maintenance doses. During this prophylactic phase of the
study, the primary efficacy parameter was the occurrence
of microscopically confirmed symptomatic malaria of
all species.
Upon return to Australia, subjects randomized to mef-
loquine and tafenoquine received either 15 mg prima-
quine twice per day for 14 days (total dose of 420 mg or
5.2 mg/kg) or placebo. There was a six month period of
follow up. The intent during this phase was to monitor
P. vivax relapses. Primaquine was given in the meflo-
quine arm because it is an effective anti-relapse agent
and mefloquine is not. A placebo was given in the tafe-
noquine arm because prior Phase II studies suggested it
was also an effective anti-relapse agent.
During the prophylactic phase of the study, there were
no symptomatic cases of malaria in either study arm.
During the six-month follow-up phase there were four
P. vivax relapses in the tafenoquine arm and one P. vivax
relapse in the mefloquine arm.
In the final clinical study report (FCSR) subsequently
submitted to the FDA by the Sponsor, the intent to treat
(ITT) populations were n = 490 for tafenoquine, and n =
161 for mefloquine. The ITT denominators were used
for the attack rate and protective efficacy calculations
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FCSR submitted to the FDA by the Sponsor, 21 subjects
were reported as being withdrawn from the study. The
Sponsor conducted a "worst case analysis" for the
intention to treat (ITT) population. Any subject that
withdrew during the prophylactic phase was considered
a failure (assumed to have had malaria). This "worst case
analysis" for the ITT population yielded a protective effi-
cacy, assuming a 100% attack rate, of 96.5% (473/490)
and 97.5% (157/161) for tafenoquine and mefloquine, re-
spectively. The assumption that withdrawn subjects were
prophylactic failures is the most conservative approach
for such an ITT efficacy analysis. Therefore, an import-
ant component of the present study was to confirm that
the individuals who withdrew from the study should not
be counted as prophylactic failures due to loss to follow-
up. This issue was not explicitly addressed in the original
public reporting of the study results [6].
ADF deployments to Timor Leste
Australian Defense Force infantry battalions commenced
peacekeeping operations in Timor Leste in September
1999 as part of International Force East Timor (Inter-
FET) under United Nations Security Resolution 1264
and with Indonesian government agreement. Table 1
summarizes the time period ADF infantry battalions
served in Timor Leste up to 30 April 2003. Later battal-
ions starting with the 5th/7th Battalion, Royal Australian
Regiment (5/7RAR) in October 1999 migrated to opera-
tions under the United Nation’s Transitional Adminis-
tration East Timor (UNTAET, Security Resolution 1272
in 1999). In contrast to ADF soldiers under InterFET,
those deployed under UNTAET experienced less exposure
to night jungle patrols compared to previous operations in
multiple regions of Timor Leste; this may have contrib-
uted to reduced vector exposure. Vector control opera-
tions also improved as lines of communication between
Australia and Timor Leste improved; soldiers gradually
re-learned basic malaria prevention procedures in infantry
units over time.
Documentation of malaria exposure during ADF
deployments to Timor Leste
Malaria is a notifiable disease in all states and territories
of Australia under the National Notifiable Disease Sur-
veillance System [20]. Australian Defence Force Health
Policy Directive 215 requires notification of malaria in-
fections in military personnel to the state or territory
health authority. In addition, all confirmed or suspected
cases of malaria in defense personnel or their dependents
(whilst on posting to malarious areas) are reported to the
Australian Army Malaria Institute (AMI) Central Malaria
Registry (CMR). Whenever possible all malaria diagnosis
is achieved with light microscopy of thick and thin bloodsmears. Diagnosis may also be performed using malaria
rapid diagnostic tests (RDTs) when accurate diagnosis by
microscopy is not available. The notification report to
AMI by defence units is accompanied by thick and thin
blood films as well as any RDT cards or other devices used
to diagnose malaria to allow AMI personnel to verify the
diagnosis and species before entry into the CMR.
The CMR was analysed over the period 1 April 1999
to 30 April 2003 for malaria cases in the infantry battal-
ions described in Table 1. Malaria cases were excluded if
the infantry soldier had a travel history to another mal-
arious country after leaving Timor Leste and their first
confirmed case of malaria. All P. vivax relapses were ex-
cluded from the analysis irrespective of country of origin.
Duplicates entries (total of 17) in the CMR database were
confirmed against the original notification and follow-up
relapse reports (if applicable) and subsequently discounted.
A limitation of the analysis is loss to follow-up of Defense
members who leave the ADF and subsequently develop
malaria after a military deployment. These cases would be
captured by state/territory health authorities but not ne-
cessarily by the ADF unless a compensation action was
commenced. The analysis was subjected to an inde-
pendent quality control review. All work complied with
the National Statement on Ethical Conduct in Human
Research (as amended) guidance on the use of identifi-
able databanks [21].
Determination of the malaria status of subjects who
withdrew from Study 033
As mentioned earlier, the FCSR report submitted to the
FDA by the Sponsor included a "worst case analysis" for
the ITT population in which subjects who withdrew
from the study were considered prophylactic failures. In
the reanalysis of Study 033, there was an attempt to con-
firm that subjects who withdrew were not in fact prophy-
lactic failures (i.e. did not get malaria) if they remained in
the ADF for up to 12 months post their 1 RAR deploy-
ment and had no other travel history to malarious areas.
Three investigators queried the CMR to determine the
malaria status of each of these subjects. As mentioned
above, a limitation of the CMR is that it captures malaria
cases only for active ADF personnel. Additional ADF re-
cords were examined to determine whether any of the
subjects withdrawn from the study left the ADF in the
twelve months following the end of Study 033.
Observed post-deployment P. vivax relapse rate during
Study 033
The number of P. vivax cases from study subjects en-
rolled in Study 033 in the CMR was determined during
a period of one year post-deployment. This observation
period was longer than that in the Study 033 final clinical
study report (6 months) because Chesson strain P. vivax
Table 1 Details of Australian infantry deployments to Timor Leste*
Battalion Dates Regions of Timor Leste Battalion strength Months
deployed
Pf attack rate (%)
Monthly/Cumul ***
Pv attack rate (%)
Monthly/Cumul
All malaria attack rate
(%) Monthly/Cumul
Prophylaxis
2 RAR** Sep 99 through Jan 00 Dili, Bobanaro district 681 4.33 0.31/1.32 2.04/8.81 2.34/10.13 Doxycycline 100 mg q.d
3RARⱡ Sep 99 through Jan 00 Dili, Bobanaro district and
Oecussi province
634 4.33 0.29/1.26 2.11/9.15 2.59/11.2 Doxycycline 100 mg q.d
5/7RAR Nov 99 through Apr 00 Dili, Bobanaro district 522 6.83 0.11/0.77 0.81/5.56 0.83/6.71 Doxcycline 100 mg q.d
6RAR Apr 00 through Oct 00 Dili, Bobanaro district 619 6.16 0.03/0.16 0.24/1.45 0.26/1.62 Doxycycline 100 mg q.d
1RAR Oct 00 through Apr 01 Dili, Bobanaro district 723 6.00 0.00/0.00 0.18/1.11 0.18/1.11 Tafenoquine 200 mg or
Mefloquine 250 mg weekly
4RAR Apr 01 through Oct 01 Dili, Bobanaro district 750 7.00 0.00/0.00 0.08/0.53 0.08/0.53 Mefloquine 250 mg weekly
2RAR Oct 01 through May 02 Dili, Bobanaro district 681 6.83 0.00/0.00 0.11/0.73 0.11/0.73 Mefloquine 250 mg weekly
3RAR Apr 02 through Oct 02 Dili, Bobanaro district 634 7.00 0.02/0.16 0.14/0.95 0.18/1.26 Doxycycline 100 mg q.d
5/7RAR Oct 02 through Dec 02 Dili, Bobanaro district 536 2.57 0.00/0.00 0.28/0.71 0.28/0.71 Doxycycline 100 mg q.d
*Values for dates deployed, battalion strength and period deployed are approximate.
**RAR = Royal Australian Regiment.
ⱡBoth 3 RAR and 5/7 RAR soldiers participated in post-exposure prevention studies (Elmes, 2008).
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days after the first day of deployment (median 83 days,
mean 105 days). As a consequence more P. vivax cases
were recorded than were reported previously (8 versus 5).
The 12 month observed post-deployment P. vivax attack
rate [ARPv (post-deployment)] was then calculated as fol-
lows (equation 1):









Where RPv = total number of P. vivax relapses and
N = total ITT sample size
Calculation of the ratio of P. falciparum to P. vivax cases
during the InterFET deployment (1999/2000)
The ratio of cases of P. falciparum to P. vivax was esti-
mated as described below and summarized in Table 2
(A-D). The 1RAR soldiers involved in the 2000/01 ADF
deployment and who were enrolled in Study 033 arrived
in country on 25 October 2000 and returned to Australia
on approximately 25 April 2001. This coincided with
the wet season and the period of highest seasonal mal-
aria prevalence in Timor Leste [9]. Three separate bat-
talions of Australian soldiers were deployed at times that
overlapped this period the year before; Second Battalion,
Royal Australian Regimen (2RAR), Third Battalion, Royal
Australian Regiment (3RAR) and the 5/7RAR. TheirTable 2 (A-D): Calculation of the 6 month cumulative attack r
1999/00 ADF deployment
A: Cumulative attack rates (%) by time period, species and battalion ex
Time period (months)/(Battalions deployed) Specie
Period 1: Oct 25 99-Oct 31 00 (0.2)/(2RAR and 3RAR) Pv/Pf/
Period 2: Nov 1 99-Jan 31 00 (3.0)/(2RAR, 3RAR and 5/7 RAR) Pv/Pf/
Period 3: Feb 1 00 – April 25 00 (2.8)/(5/7RAR) Pv/Pf/
B: Estimate of overall cumulative attack rate (%) by period for ALL batt
Time period (months) Specie
Period 1: Oct 25 99-Oct 31 99 (0.2) Pv/Pf/
Period 2: Nov 1 99-Jan 31–00 (3.0) Pv/Pf/
Period 3: Feb 1 00 – April 25 00 (2.8) Pv/Pf/
C: Estimate of the 6 month cumulative attack rate for battalions expos
Time period (months) Specie
Periods 1, 2 and 3:Oct 25 99-April 25 00 (6.0) Pv/Pf/
D: Estimate of Pf to Pv ratio for all battalions exposed during
the 1999/00 ADF deployment***
0.146
*Overall attack rates are the weighted averages of attack rates for battalions expose
**Cumulative attack rate (probability) = P1 + (1-P1)*P2 + (1-P1)(1-P2)*P3 where P1, P2 a
***Cumulative Pf attack for all battalions (from Table 2C)/Cumulative Pv attack ratemalaria exposure was assumed to be the most relevant
because it also coincided with period of highest seasonal
malaria prevalence. A fourth, the 6th Battalion, Royal
Australian Regiment (6RAR), was deployed in the six
months prior to 1RAR in which conditions were drier,
and in which the incidence of malaria is usually lower
[9]. Together, the 2RAR, 3RAR, and 5/7 RAR were de-
ployed for three periods of overlapping exposure which
were relevant. Period 1 was October 25 to October 31
1999, and includes only 2RAR and 3RAR since 5/7 RAR
was not yet deployed. Period 2 was from November 1
1999 to January 31 2000 and included 2RAR, 3RAR and
5/7RAR. Period 3 was from February 1 2000 to April 25
2000 and includes only 5/7 RAR since the other battal-
ions had returned to Australia.
Table 2A summarizes for each period and regiment,
the P. falciparum, P. vivax, and all species malaria attack
rates (AR) calculated as follows (equation 2):
AR in periodð ÞPv;Pf ;all¼
total casesð ÞPv;Pf ;all
person‐months deploymentð Þ
 
 months in periodð Þ100%
ð2Þ
During each of these three time periods, an overall
(weighted average) attack rate was calculated with weights
based on the number of soldiers in each battalion
(Table 2B). Using the overall attack rates (decimal) for
each period as estimates of the malaria risk (probability),
the estimate of the cumulative 6 month attack rate [((AR
(6 month), Table 2C) for each species and all speciesate ( Pf, Pv, all species) and Pf to Pv ratio during the
posed during the 1999/2000 ADF deployment*
s 2RAR (n = 681) 3RAR (n = 634) 5/7RAR (n = 522)
All species 0.41/0.06/0.47 0.44/0.07/0.52 NA/NA/NA
All species 6.10/0.92/7.02 6.56/0.98/7.76 2.52/0.34/2.95
All species NA/NA/NA NA/NA/NA 2.38/0.32/2.78
alions exposed during the 1999/2000 ADF deployment*




ed during the 1999/00 ADF deployment**
s Cumulative attack rates for all battalions
All species 7.89/1.15/9.18
(1.15/7.89)
d during the period (weights = sample size).
nd P3 are the estimated overall attack rates for periods 1, 2 and 3 (from Table 2B).
for all battalions (from Table 2C).
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(equation 3):
AR six monthð ÞPv;Pf ;all¼ARP1 þ 1−ARP1ð ÞARP2
þ 1−ARP1ð Þ 1−ARP2ð ÞARP3
ð3Þ
The P. falciparum to P. vivax ratio (Pf:Pv) was then
determined (Table 2D) as follows (equation 4):
Pf : Pv¼ AR 6 monthð ÞPf






Assumed anti-relapse efficacy/effectiveness of Study
033 regimens
For estimation of the P. vivax attack rate during the
prophylactic phase, it was assumed that the anti-relapse
efficacy/effectiveness of the combined (AREcombined) post-
exposure prophylaxis regimens (tafenoquine or prima-
quine) was 82.1%. This was obtained as a weighted average
of estimates of the anti-relapse efficacy/effectiveness of















Where NTq and NMef are the ITT sample sizes in the
post-exposure tafenoquine and mefloquine arms of Study
033 and ARETq and AREPq are the anti-relapse efficacies/ef-
fectiveness of tafenoquine and primaquine determined from
published studies as outlined in the following paragraphs.
AREPq was based on pooled data from a number of his-
torical studies in which the relapse rate in a chloroquine
only arm (26.5%; 420/1585) was compared with chloro-
quine + 2.5- < 5 mg/kg primaquine (8.08%; 140/1732 ) as
reported by [15]. Based on these relapse rates, the assumed
AREPq is 69.5% ([(0.265-0.0808)/0.265]100%). Note that this
represents the effectiveness of primaquine in this context
because administration of the drug in many of the studies
analysed by John et al. (2012) was not directly observed.
The assumed anti-relapse efficacy of tafenoquine (ARETq)
was based on data reported by Walsh et al. [4]. Walsh et al.
investigated the prophylactic efficacy of tafenoquine ad-
ministered as a loading dose of 400 mg × 3, followed by
monthly maintenance doses of 400 mg for five months
versus placebo in deployed Thai soldiers. P. vivax relapses
were observed in 3.1% (3/96) of subjects randomized to
tafenoquine and completing the study, where as 22.8%
(21/92) of subjects randomized to placebo who completed
the study contracted P. vivax in the prophylactic phase
[4]. In that study, subjects in the placebo control arm whocontracted malaria were administered a curative regimen
and recruited for a subsequent tafenoquine pharmacokinetic
study, meaning that the P. vivax relapse rate in this arm is
not known. It was assumed the P. vivax relapse rate in that
study was 100%. Therefore, the assumed anti-relapse rate
of tafenoquine was 86.3% ([(0.228 – 0.031)/0.228]100%).
Estimated malaria attack rate during Study 033
The estimated all malaria attack rate during the six-month
prophylactic phase of Study 033 was calculated as the sum
of the estimated six month attack rates for P. vivax and
P. falciparum as follows (equation 6).
AR prophylaxis phaseð Þall
¼ ARPv þ ARPf 6:88%þ 1:00% ¼ 7:88%½ 
ð6Þ
The calculations are further summarized in Table 3.
Note that species other than P. vivax and P. falciparum
were excluded.
The P. vivax attack rate (ARPv) during the prophylaxis
phase was estimated by adjusting the total observed re-
lapse rate of 1.229% (8/651) during the post-deployment
period to take into account the combined anti-relapse
efficacy of 82.1% in the tafenoquine and mefloquine/
primaquine arms (Eqn 5; Table 3) as follows (equation 7)






It was assumed that all P. vivax cases that would have
been observed in the prophylactic phase would also have
relapsed in the absence of post-exposure prophylaxis. The
observed P. vivax relapse rate during the post-deployment
period of Study 033 (1.229%) was determined using data
from the CMR as described earlier.
The estimate of the P. falciparum attack rate during the
six-month prophylaxis was based on the estimate of the
P. vivax attack rate during the prophylaxis phase (6.88%;
from equation 7) and the ratio of P. falciparum relative to
P. vivax (0.146, from equation 4) based on epidemiological
data from the 1999/00 ADF deployments to Timor Leste
(Table 2) and calculated as follows (equation 8).
ARPf prophylaxis phaseð Þ¼ARPv Pf : Pv ratioð Þ
6:88% 0:146ð Þ ¼ 1:00%½ 
ð8Þ
Calculation of the protective efficacy and confidence
intervals for tafenoquine and mefloquine
The usual definition of the protective (prophylactic) efficacy
(PE) in a placebo-controlled trial was used to determine the
Table 3 Estimation of malaria attack (Pv, Pf, all species) during the prophylactic phase (6 month) of Study 033
Data* Value** Source
Post deployment P. vivax relapse rate (%) amongst Study 033 subjects 1.23 Pv relapses (8/651) from CMR not original Study 033
FCSR (Equation 1)
Anti-relapse effectiveness (%) of primaquine 69.5 Estimated from John et al. 2012
Anti-relapse efficacy (%) of tafenoquine 86.3 Estimated from Walsh et al. 2004b
Anti-relapse efficacy of combined Study 033 post-exposure
prophylaxis regimens
82.1 Estimated (Equation 5)
Pv attack rate (%) during prophylactic phase of Study 033 6.88 Estimated (Equation 7)
Ratio of Pf cases to Pv cases in 1999/2000 ADF deployment (InterFET) 0.146 Observed from 1999/2000 ADF deployment (Equation 4)
Pf attack rate (%) during prophylactic phase of Study 033 1.00 Estimated (Equation 8)
All malaria attack rate (%) during prophylactic phase of Study 033 7.88 Estimated (Equation 6)
*Observed in Study 033, ADF deployment, assumed from literature or derived. **Rounded after calculation.
Table 4 Effect of using a constant baseline attack rate on
the precision (confidence interval) of the estimated
protective efficacy of tafenoquine compared to assuming
an attack rate based on results from hypothetical
placebo controlled trials with different sample sizes
ARPl (cases/n)
1 ARTq (cases/n)
2 PETq LL (PETq)
3
1% (1/100) 0 (0/490) 100% 45% (44.87)
1% (10/1000) 0 (0/490) 100% 45% (44.91)
1% (constant)4 0 (0/490) 100% 44% (44.10)
2% (1/50) 0 (0/490) 100% 72% (72.43)
2% (2/100) 0 (0/490) 100% 72% (72.46)
2% (constant)4 0 (0/490) 100% 73% (72.54)
3% (3/100) 0 (0/490) 100% 82% (81.65)
3% (30/1000) 0 (0/490) 100% 82% (81.69)
3% (constant)4 0 (0/490) 100% 82% (81.70)
5% (1/20) 0 (0/490) 100% 89% (88.97)
5% (2/40) 0 (0/490) 100% 89% (88.98)
5% (5/100) 0 (0/490) 100% 89% (88.99)
5% (50/1000) 0 ( 0/490) 100% 89% (89.02)
5% (constant)4 0 (0/490) 100% 89% (89.02)
10% (1/10) 0 (0/490) 100% 94% (94.49)
10% (5/50) 0 (0/490) 100% 95% (94.50)
10% (10/100) 0 (0/490) 100% 95% (94.50)
10% (100/1000) 0 (0/490) 100% 95% (94.51)
10% (constant)4 0 (0/490) 100% 95% (94.51)
1Placebo attack rate based on hypothetical trial results (cases/n) or assumed to
be a known constant value (no variability).
2Observed attack rate for tafenoquine in Study 033.
3Lower limit of the one-side 95% CI for the protective efficacy of tafenoquine
[LL(PETq)]. Koopman's (score test) method was used when the placebo attack
rate (ARPl) is based on hypothetical placebo results (cases/n). StatXact (vs.9.0)
was used for calculations and the confidence level was set to 90% [for ARTq = 0
(0/n) this gives a lower limit of a one-sided 95% interval for PETq].
4When ARPl is assumed to be a known constant equation 11(bottom) was
used to obtain LL(PETq).
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Where ARTq and ARPl are the cumulative risk esti-
mates (cumulative attack rates) for the period of prophy-
laxis in those receiving tafenoquine compared to those
receiving a hypothetical placebo. A similar definition ap-
plies to the protective efficacy of mefloquine (PEMef ).
Since Study 033 had no placebo control arm, conven-
tional calculation of protective efficacy and correspond-
ing confidence interval (CI) was not possible. Because in
Study 033 there were no cases of malaria it should be
noted that, for any estimated attack rate, the point esti-
mate PETq and PEMef would be 100%. However, standard
methods for calculating a confidence interval (CI) for PE
(Tq or Mef) depend on the placebo attack rate and sample
size. To determine the PE and CI it was assumed that the
attack rate (ARPl) would have been the estimated all malaria
attack rate of 7.88% calculated above (equation 6) during
the prophylactic phase of Study 033. In addition a constant
ARPl was (= 7.88%) used for calculating corresponding 95%
CIs for PE. A sensitivity analysis of this assumption was car-
ried out (Table 4, see below). In the remainder of this dis-
cussion the estimated all malaria attack rate (=7.88%) will
be referred to as the “estimated AR” (ARPl).
The attack rate for tafenoquine (ARTq) and mefloquine
(ARMef ) during the prophylactic phase was determined
based on the ITT results of study 033 [0 cases; sample size
of 490 (Tq) and 161 (Mef)] and were computed as follows
(equation 10):
ARTq;Mef prophylaxis phaseð Þ ¼
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puting the lower and upper limits (LL, UL) for a propor-
tion (ARTq or ARMef) using the Wilson (score) method,
and then converting these limits into corresponding limits
for PE (assuming ARPl = 7.88%). When there are 0 cases,
AR = 0 (0/n) and the lower confidence limit for AR is al-
ways 0 and the corresponding upper limit for PE is 100%.
Given lower and upper Wilson confidence limits for the
attack rates (LL AR, ULAR) the corresponding limits for PE
(Tq or Mef) are therefore given as follows (equation 11):
LLPE ¼ 1− ULAR0:0788
 
100%









The above method for determining a confidence inter-
val for PE assumes a constant estimated AR (7.88%).
This assumption does not take into account additional
variability had the malaria exposure during Study 033
been estimated based on results from a placebo control
arm (with a given sample size). A sensitivity analysis was
conducted (Table 4) to determine the effect of assuming
a constant estimated attack rate on the resulting 95%
lower confidence limit for the protective efficacy of tafe-
noquine [LL(PETq)]. Hypothetical estimated attack rates
(ARPl) from 1% -10% and sample sizes (nPL) from 10–
1000 were considered. Combinations of ARPl and nPl
were selected to give integer values for the correspond-
ing number of placebo cases (nPL × ARPL). All calcula-
tions assumed no observed cases in the tafenoquine arm
and a sample size (ITT) of n = 490 (Study 033 results).
Over the range of ARPl considered (1%-10%) the esti-
mate of the lower limit of the 95% confidence interval
(one-sided) for PETq did not vary substantially with changes
in sample size (<1% change, see Table 4). The minimal ef-
fect of sample size on LL(PETq) is because there were no
observed malaria cases and the sample size in the tafeno-
quine arm employed in Study 033 was large (ITT n = 490).
For a given ARPl and nPl, Koopman's (score test) method
was used for computing the lower 95% limit for PE. Stat-
Xact (vs. 9.0) was used and the confidence level was set
to 90% (gives lower limit of a one-sided 95% interval
and is the convention used when the point estimate for
PE = 100%).
Results
The observed attack rates for P. falciparum and P. vivax
are tabulated for each ADF deployment in Table 1. All
malaria species attack rates for 2RAR, 3RAR and 5/7
RAR were 10.13%, 11.20% and 6.71%, respectively (Table 1).
All species attack rates were substantially lower for subse-
quent deployments (including 1 RAR), ranging from 0.53-1.62% (Table 1). The aggregate P. falciparum and P. vivax
attack rates during the 1999/2000 deployments were 7.88%
and 1.15%, yielding a P. falciparum to P. vivax species ratio
of 0.146 (Table 2). For the 1 RAR deployment from 25
October 2000 to 25 April 2001, eight post-deployment
P. vivax cases were observed amongst a deployed popu-
lation of 723, yielding an observed post-deployment re-
lapse rate of 1.11%.
All eight P. vivax cases following the 1RAR deploy-
ment were amongst individuals recruited for Study 033
(note that not all 723 1RAR soldiers were recruited for
Study 033). Thus, the observed post-deployment P. vivax
relapse rate during Study 033 was 1.23% (8/651). The
number of P. vivax relapses observed (8) was higher than
reported previously [6]. This was a consequence of ex-
tending the observation period from six months (per the
study design) to 12 months due to additional data re-
ported to the ADF’s CMR. The all malaria attack rate dur-
ing the prophylactic phase of Study 033 was estimated to
be 7.88% (see summary in Table 3). The CMR contained
no records of malaria cases amongst 20 of 21 withdrawn
subjects who remained in the ADF for twelve months fol-
lowing Study 033. A single withdrawn subject, random-
ized to the mefloquine arm, remained in the ADF for 11
months following Study 033. The CMR also contained no
record of that subject having contracted malaria during
this period.
In Study 033, of 490 ITT subjects given tafenoquine
and 161 ITT subjects given mefloquine, no symptomatic
cases of malaria were observed during the prophylactic
phase ([6], see Table 5). None of the subjects listed as
withdrawn from the study in the FCSR were found to
have contracted malaria during the prophylactic phase.
Therefore, the protective efficacy of both regimens was
100%. Utilizing the all species malaria attack rate of 7.88%
during the prophylactic phase of the study as the esti-
mated attack rate, the lower limits of the 95% confidence
interval (one-sided, as outlined in Methods) for the pro-
tective efficacy of tafenoquine and mefloquine were 93%
and 79%, respectively (Table 5).
Discussion
This paper describes methodology for calculating protect-
ive efficacy when there is no concurrent placebo control
arm data. Using this methodology, it was possible to dem-
onstrate that tafenoquine exhibited a protective efficacy of
100% with a 95% lower confidence limit of 93% while
mefloquine exhibited a protective efficacy of 100% with
a 95% lower confidence limit of 79%. The lower value of
the lower limit for mefloquine is due to the smaller sam-
ple size (161 vs 490). These calculations are based on a
retrospective estimate of an attack rate of 7.88%. That
attack rate was calculated based on the following assump-
tions: (i) that the P. falciparum:P. vivax species ratio in
Table 5 Protective efficacy (and confidence interval) for mefloquine and tafenoquine for malaria prophylaxis in non-immune
Australian soldiers deployed to Timor Leste for six months in 2000/2001 (an attack rate of 7.88% was assumed)
Results during the prophylactic
phase of Study 033
Protective efficacy (PE) during
prophylactic phase of Study 033
Drug ITT Population Malaria cases Subjects lost to follow-up Drug attack rate
(%) (95% CI)*
PE (%)** 95% CI***
Mefloquine 161 0 0 0 (0, 0.549) 100 79 - 100
Tafenoquine 490 0 0 0 (0, 1.653) 100 93 – 100
*Confidence interval (CI) for the attack rate (AR) is based on Wilson (score) method for proportions. In the special case when AR = 0 (0/n), the upper limit
corresponds to a one-sided upper 95% limit. For AR = 0, the lower limit is set to zero.
**PE = [1 – drug AR/0.0788)]100. For zero cases, PE = 100%.
***95% CI for protective efficacy (PE) obtained from corresponding limits for the drug attack rates. The lower limit for PE = [1- AR upper limit/0.0788] x 100. The
upper AR limits for tafenoquine (0/490) and mefloquine (0/161) are 0.549% and 1.653%. For PE = 100%, the upper limit is set to 100%.
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Australian soldiers in the 1999/2000 deployment, (ii) that
the anti-relapse effectiveness of primaquine at the dose
used in Study 033 was 69.5%, and (iii) that the anti-relapse
efficacy of the tafenoquine dose used in Study 033 was
86.3%. These assumptions are conservative for the reasons
outlined in the following paragraphs. Therefore, the attack
rate reported in this study is likely to be an under-estimate.
The utilization of a P. falciparum:P. vivax ratio based
on observed cases in Australian soldiers in 1999/2000 is
the most conservative of the reasonable alternatives. It
could have been assumed that there was no P. falciparum
malaria during the 1 RAR deployment, since none was
directly observed. Alternatively, the higher P. falciparum:
P. vivax ratios observed in the unprophylaxed civilian
population living close to garrisoned Australia soldiers
during Study 033 (~1:1) or the ~2:1 ratio observed for
malaria cases originating amongst Australian soldiers in
Timor Leste during the 1999–2000 deployment [7,12]
could have been used. Assuming no exposure to
P. falciparum would not have been reasonable given that
there was clearly transmission of P. falciparum amongst the
civilian population living close to the 1 RAR garrison posi-
tions [7]. Assuming P. falciparum:P. vivax ratios of 1:1 or
2:1 would imply attack rates of 14% and 22% respectively.
However, this would have assumed either parity in malaria
exposure between unprophylaxed civilians and soldiers, or
that compliance with doxycycline and primaquine prophy-
laxis could be estimated in the absence of data (remember
that in Study 033 compliance with medications was re-
corded whereas in the 1999–2000 deployment it was not).
While these assumptions may be defensible, the more
conservative of the reasonable approaches was taken.
Using data from John et al. [15], it was assumed that
the anti-relapse efficacy of the primaquine regimen used in
Study 033 was 69.5%. This is likely to have been an under-
estimate since the dose used in Study 033 (5.2 mg/kg) is
higher than that (2.5 - <5 mg/kg) for which John et al. pro-
vide data. It was decided to use effectiveness data for low
dose primaquine (2.5 - < 5 mg/kg) because there are onlytwo studies in the literature which have compared relapse
rates for a blood schizonticidal drug with and without high
dose primaquine (> 5 mg/kg). Neither of these is directly
analogous to Study 033. Baird et al. [22] reported that
the anti-relapse efficacy of 10 mg/kg primaquine in
combination with a standard chloroquine regimen in
Irian Jaya was 82.3% relative to chloroquine alone after
28 days follow-up. However, the higher dose (10 mg/kg
v 5.2 mg/kg in Study 033), short follow-up period (one
month versus 12 months in Study 033) and the presence
of chloroquine-resistance P. vivax in Irian Jaya (recur-
rences may be recrudescences not true relapses) are
confounding. Leslie et al. [23] reported a higher anti-
relapse efficacy for high dose primaquine in Pakistan.
However, reliance on a single study from South Asia
would have been inappropriate since recurrence rates
following primaquine administration may be lower there
than in South East Asia.
The assumed anti-relapse efficacy of tafenoquine of
86.3% was calculated using data for a prophylactic regimen
of tafenoquine that was different from that used in Study
033 [4]. This is likely to have been an under-estimate since
pharmacokinetic modeling studies suggest that this regi-
men (400 mg per day for three days followed by monthly
maintenance doses) generates lower overall exposure levels
than the Study 033 regimen despite the higher loading
dose (Dow et al., unpublished observations). The calcula-
tions also assume similar P. vivax relapse rates and suscep-
tibility to tafenoquine in Thailand and Timor Leste. This is
reasonable given the long follow-up times in both the
Walsh study and Study 033, and the lack of evidence
suggesting any regional differences in susceptibility to
8-aminoquinolines in the western Pacific.
Mefloquine is an effective anti-malarial drug and re-
mains the standard of care for weekly malaria prophy-
laxis where this is justified by the risk:benefit context.
The reported efficacy of mefloquine prophylaxis in mal-
aria naïve individuals is broadly similar to the efficacy
of tafenoquine reported in this and prior clinical re-
ports. In U.S. Peace Corps volunteers stationed in East
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chloroquine-resistant, the protective efficacy (95% CI) of
mefloquine prophylaxis relative to chloroquine and chloro-
quine/proguanil prophylaxis was 94% (86-97%) and 86%
(67-94%) respectively [24]. Presumably these also represent
under-estimates of the true efficacy of mefloquine because
both chloroquine and chloroquine-proguanil presumably
have greater efficacy than placebo. In European tourists
travelling to East Africa, the protective efficacy of meflo-
quine prophylaxis relative to no malaria prophylaxis was
94% [25].
The protective efficacy of tafenoquine and mefloquine
during the deployment period in Study 033 was 100%
since no symptomatic cases of malaria were observed.
This was lower than the level of prophylactic efficacy of
the same drugs (~86% for both drugs) observed amongst
semi-immune residents of Ghana in one of the Phase II
studies [2]. This seems counter-intuitive given the con-
ventional wisdom that prophylactic anti-malarials should
be more effective in non-immunes than semi-immunes
due to the presumably enhancing effect of immunity in
the latter group. However, it is not known whether this
hypothesis is correct and there has not been a systematic
review of the literature addressing this question. Also,
there is a paucity of placebo-controlled field studies that
have definitively determined the prophylactic efficacy of
approved regimens in non-immune travellers since these
are very challenging to perform. In the specific case of
the Ghana [2] and Study 033, it is reasonable to specu-
late that the apparent differences in efficacy may be due
to false positive microscopy. Even in a high attack rate
setting, small rates of false positive microscopy (<1%)
may result in an underestimate of true prophylactic effi-
cacy that is of the order of magnitude of the difference
in efficacy observed between the Ghana and Study 033
[26]. Furthermore, in a study involving non-immunes, a
true malaria case, whether correctly or incorrectly diag-
nosed using microscopy, is likely to be recognized as
such by the study team because it will be symptomatic.
This is less likely to be the case in semi-immunes where
it is routine to detect parasites by microscopy in individ-
uals who are asymptomatic.
The conclusion that prophylactic efficacy of tafeno-
quine and mefloquine was 100% in Study 033 applies
only to the period of time between the first dose of the
drug and the first dose of post-deployment medication.
In the case of mefloquine the persisting risk of a post-
deployment case of P. falciparum malaria from a late de-
ployment exposure is managed through administration
of additional weekly doses of the drug for four weeks,
while the risk of P. vivax relapses is managed through
administration of primaquine (as in Study 033). In the
case of tafenoquine, it is known that symptomatic fail-
ures occur when plasma levels of the drug fall below80 ng/ml [27]. Therefore, it is anticipated that add-
itional administration of tafenoquine will be required post-
deployment to manage the residual risk of P. falciparum
cases, although the precise regimen has not been de-
termined. Based on open-label clinical studies [16], a
residual risk of post-deployment P. vivax relapses of
approximately the same magnitude as primaquine can
be anticipated.
The population that may benefit the most from drugs
for malaria prophylaxis are non-immune individuals de-
ployed or travelling to areas with endemic malaria, although
in some cases prophylaxis may also have considerable utility
for malaria control efforts in endemic countries. In the con-
text of a clinical study to determine the protective efficacy
of a new prophylactic anti-malarial in non-immune individ-
uals, it may be very challenging to directly determine an at-
tack rate if the use of a placebo is not feasible. During a
military engagement, placebo control arms are generally
not used because of their possible impact on mission effect-
iveness. As argued elsewhere [5], the use of placebo in non-
immune individuals more generally is acceptable if it does
not expose study participants to a substantial risk of severe
illness or death. This is feasible in Phase I challenge studies
but may not be in a deployed setting for military or civilian
participants. In the specific context of a prophylaxis study
involving a deploying military force, if preparations for exe-
cution of the study are conducted rapidly there may be in-
sufficient time to adequately document malaria exposure
for two prior years as required by the FDA guidance [11].
One approach to determining a well-characterized attack
rate would be to radically cure a cohort of civilians resident
in the same area, and prospectively document new infec-
tions. Necessarily this assumes that civilian and military ex-
posure to malaria is the same. The method described here,
with different inherent assumptions, whereby an attack rate
during the prophylactic phase is estimated based on adjust-
ment of the observed post-deployment P. vivax relapse rate
during follow-up to account for the anti-relapse efficacy of
the study drugs, is an alternative approach that could be
considered.
Conclusions
This study retrospectively determined a conservative es-
timate of 7.88% for the all species malaria attack rate to
which Australian Defence Forces personnel on peace-
keeping duties in Timor Leste were exposed during their
participation in a Phase III prophylaxis study to evaluate
the prophylactic efficacy of tafenoquine and mefloquine.
The prophylactic efficacy of mefloquine and tafenoquine
during the period between administration of the first
prophylactic dose and the first dose of post deployment
medication was 100% (93-100%) and 100% (79-100%)
respectively. The methodology employed to determine
an attack retrospectively in the absence of placebo
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ture prophylactic studies involving malaria naïve sub-
jects in which it is not feasible to include a placebo
control arm.
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